David Sallman

66PUBLICATIONS
435CO-AUTHORS
Regenerative medicine (incl. stem cells)Haematological tumoursMedical mycologyGene and molecular therapyMedical molecular engineering of nucleic acids and proteins
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (66)

|Aug 27, 2026
Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients With Higher-Risk Myelodysplastic Syndromes/Neoplasms: An analysis From the International Consortium for MDS (icMDS).

|Jul 29, 2026
Clinical and Genomic Convergence of High-Risk CCUS and Lower-Risk Myelodysplastic Syndromes/Neoplasms.

|Jul 13, 2026
Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE Study.

|Jul 01, 2026
Spatial remodeling of bone marrow architecture defines tissue-state signatures of disease activity and therapeutic response in myelodysplastic neoplasms.

|Jun 29, 2026
Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE database.

|May 06, 2026
Cardiovascular Adverse Events During Venetoclax-Based Treatment in Acute Myeloid Leukemia.

Pageof 11

Frequent Collaborators

45 joint publications

Rami S Komrokji

20 joint publications

Eric Padron

14 joint publications

Jeffrey Lancet

14 joint publications

Onyee Chan